The graph below shows the risk of developing VTE for women who are not pregnant and do not use CHCs, for women who use CHCs with a range of doses and routes of administration, for pregnant women, and for women in the postpartum period.
XULANE is indicated for the prevention of pregnancy in women with a body mass index (BMI) < 30 kg/m2 for whom a combined hormonal contraceptive is appropriate.
XULANE may be less effective in preventing pregnancy in women who weigh 198 lbs. (90 kg) or more. XULANE is contraindicated for use in women with BMI ≥ 30 kg/m2 [see Contraindications (4), Warnings and Precautions (5.1) and Clinical Studies (14)].
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS and CONTRAINDICATED IN WOMEN WITH A BMI ≥ 30 kg/m2
Patients should be counseled that XULANE does not protect against HIV infection (AIDS) and other sexually transmitted infections.
This is not all of the information you should read prior to prescribing XULANE. Click here for Full Prescribing Information, including Boxed WARNING.
Sign up to receive product updates and helpful resources and tools.
Intended for US residents only. Mylan Pharmaceuticals understands that your personal and health information is private. The information you provide will only be used by Mylan Pharmaceuticals and parties acting on its behalf to send you the materials you requested and other helpful information and updates on Xulane , as well as related treatments, products, offers and service. You may remove yourself from this mailing list at any time by clicking "unsubscribe" on any e-newsletters or other communications that you receive. To learn about how Mylan uses your information, please view our Privacy Statement.